This competitive renewal is based on work demonstrating that a subpopulation of endothelial cells (ECs) in atherosclerotic plaques undergo a transition to a mesenchymal cell fate that involves loss of barrier function, expression of inflammatory genes and remodeling of the extracellular matrix. This transition is initiated by inflammatory signaling that sensitizes cells to TGF?, which then drives the mesenchymal fate transition. A key consequence of the mesenchymal phenotype is production of a fibronectin-rich extracellular matrix that amplifies inflammatory signaling, recruiting leukocytes and production of cytokines. This sequence of events thus creates positive feedback, a key feature of disease progression and resistance to therapy. Our work during the past grant cycle has provided evidence that fate switching is driven by a minor subset of pre-existing, susceptible ECs that drive vessel wall remodeling. Our work has also elucidated novel pathways by which matrix remodeling alters integrin signaling to enhance inflammatory pathways and promotes disease progression. The overall goal of the current application is to understand the EC subpopulations and factors that drive fate switching, and the positive feedback mechanisms that drive disease.
Aim 1 will elucidate endothelial heterogeneity in mice and in patients with atherosclerosis.
Aim 2 will characterize disease-prone subset of normal endothelial cells.
Aim 3 will elucidate the role of pro-inflammatory integrin signaling in evolution of EC populations in the atherosclerotic plaque and the downstream pathways that mediate plaque progression.

Public Health Relevance

Atherosclerosis is an inflammatory/metabolic disease in which cells of the artery wall remodel to form a plaque that can narrow vessel lumens or rupture and block blood flow. This grant aims to understand the changes in endothelial cell fate that govern vessel remodeling and the pathways by which these changes promote disease. We will identify spatial and gene expression characteristics of susceptible EC subpopulations that mediate these transitions and elucidate the cellular positive feedback loops that mediate disease progression.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL135582-05
Application #
9973898
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Olive, Michelle
Project Start
2017-01-12
Project End
2024-12-31
Budget Start
2021-01-20
Budget End
2021-12-31
Support Year
5
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Schwartz, Martin A; Vestweber, Dietmar; Simons, Michael (2018) A unifying concept in vascular health and disease. Science 360:270-271
Chen, Pei-Yu; Simons, Michael (2018) Fibroblast growth factor-transforming growth factor beta dialogues, endothelial cell to mesenchymal transition, and atherosclerosis. Curr Opin Lipidol 29:397-403
Chen, Dongying; Simons, Michael (2018) Reprogramming the Endocardium: Trials and Tribulations. Circ Res 122:913-915
Zhang, Feng; Zarkada, Georgia; Han, Jinah et al. (2018) Lacteal junction zippering protects against diet-induced obesity. Science 361:599-603